Category Archives: Transhuman News

NYC demonstrators rally against COVID-19 vaccine requirements

NY Gov. Kathy Hochul has said she will take steps to replace medical personnel who refuse to meet the vaccination requirement.

USA TODAY, Associated Press

As COVID-19 vaccine mandates take effect across the U.S., one article circulating on social media claims getting jabbed in the arm may no longer be necessary.

"Vaccine Hesitant?" reads the headline of the Sept. 21 article published by an online outlet called Vision Times. "US Researchers Are Engineering Lettuce and Spinach to Carry mRNA COVID Jabs."

A University of California, Riverside research group, in collaboration with the University of California San Diego and Carnegie Mellon University, is reported as spearheading the scientific effort. The article details the study's research plans but makes no additional mention of the headline's reference to COVID-19 vaccines aside from describing how the mRNA vaccines work.

Fact check: Inhaling hydrogen peroxide for COVID-19 is dangerous, experts warn

The potential for splicing COVID-19 vaccines into food was echoed by former National Security Adviser Michael Flynn during a recent appearance on a podcast called "Thrivetime Show: Business School Without the B.S." In a viral clip shared to Twitter on Sept. 22, Flynn says he read an article where "they're talking about putting the (COVID-19) vaccine into salad dressings or salad."

As far-fetched as vaccine-infusedspinach and lettuce sounds, the claim is not entirely unfounded.

Researchers at UC Riverside and its collaborating universities are working on potentially turning plants into edible vaccine factories. But they'renot doing itfor COVID-19 specifically, and such foods won't be available in your local supermarket anytime soon.

USA TODAY reached out to Vision Times and Flynn for comment.

The National Science Foundation gave a UC Riversideresearch group $500,000 to study genetically engineering plants with mRNA, a molecule contained in the Pfizer-BioNTech and Moderna COVID-19 vaccines that isnormally used by our cells to make protein.

The effort was announced in a Sept. 16 press release.

Fact check: COVID-19 vaccination has no effect on blood color

But the study is looking generally toward all mRNA vaccines not COVID-19 specifically andwon't be available for human useanytime soon, said lead researcher Juan Pablo Giraldo, associate professor in the department of botany and plant sciences.

"This research will take a couple of years to show proof of concept of the technology," he wrote in an email to USA TODAY. "If successful, it will need more studies and several more years for people to use leafy greens as mRNA vaccine factories."

The idea behind using plantshas to do with mRNA vaccines' temperature requirements. Because the molecule needs to be transported and stored under cold conditions to maintainstability, researchers hope their study will help overcome this challenge and enable storage at room temperatures, according to the press release.

Fact check: False claim that cancer has spiked as a result of COVID-19 vaccines

In order to achieve this, genetic material contained in mRNA vaccines will be inserted into small, disk-like structures within plant cells called chloroplasts, solar panel-like structures that convert sunlight into chemical energy.

"Ideally, a single plant would produce enough mRNA to vaccinate a single person," Giraldo said in the release. "We are testing this approach with spinach and lettuce and have long-term goals of people growing it in their own gardens. Farmers could also eventually grow entire fields of it."

Based on our research, we rate PARTLY FALSE the claim spinach and lettuce are being genetically engineered with COVID-19 mRNA vaccines. Researchers at UC Riverside are indeed studying whether edible plants like spinach and lettuce can be genetically engineered to produce genetic material contained in mRNA vaccines. But thestudy isn't geared specifically toward COVID-19 vaccines. And the effort is in its infancy,meaning a product in this vein is years away from becoming reality.

Thank you for supporting our journalism. You can subscribe to our print edition, ad-free app or electronic newspaper replica here.

Our fact-check work is supported in part by a grant from Facebook.

Originally posted here:
Fact check: Genetically engineering your salad with the COVID-19 vaccines? We're not there yet. - USA TODAY

Olly Mannand The Week delve behind the headlines and debate what really matters.

You can subscribe to The Week Unwrapped wherever you get your podcasts:

In this weeks episode, we discuss:

The UK government has announced plans to allow gene-editing to be used in agricultural crops, diverging from an EU-wide ban on any genetic modification. Proponents of the technique say that it is more like accelerated selective breeding than genetic engineering - and that it could help farmers grow more produce while using fewer pesticides. But its opponents are worried that it will pave the way for riskier experiments.

A landmark legal case has begun between two stand-up comedians over who owns the rights to a comedy routine. One has hired Harbottle & Lewis, the lawyers best known for representing the Queen, to argue his case. So are we going to see lots of comedians taking one another to court? And how can you really establish who owns a joke anyway?

TikTok videos with the manifestation hashtag have been viewed a whopping ten billion times on TikTok, making it a buzzword of 2021. Its the latest incarnation of cosmic ordering - the practice of asking the universe to deliver what you expect from it, whether thats exam success or romantic fulfilment. Is it just harmless fun, or does it have a darker side to it?

Visit link:
Gene editing, joke theft and manifesting - The Week UK

If the Human Genome Project (HGP) was an actual human, he or she would be a revolutionary whiz kid. A prodigy in the vein of Mozart. One who changed the biomedical universe forever as a teenager, but ultimately has much more to offer in the way of transforming mankind.

Its been 20 years since scientists published the first draft of the human genome. Since its launch in the 90s, the HGP fundamentally altered how we understand our genetic blueprint, our evolution, and the diagnosis and treatment of diseases. It spawned famous offspring, including gene therapy, mRNA vaccines, and CRISPR. Its the parent to HGP-Write, a global consortium that seeks to rewrite life.

Yet as genome sequencing costs and time continue to dive, the question remains: what have we actually learned from the HGP? After two decades, is it becoming obsolete, with a new generation of genomic data in the making? And with controversial uses such as designer babies, human-animal chimeras, organs-in-a-tube, and shaky genetic privacy, how is the legacy of the HGP guiding the future of humanity?

In a special issue of Science, scientists across the globe took a deep dive into the lessons learned from the worlds first biomedical moonshot. Although some hoped having the human genome in hand would let us sprint to medical miracles, the field is more an ongoing relay race of contributions from genomic studies, wrote Science senior editor Laura Zahn.

Decoding, reworking, and potentially one day augmenting the human genome is an ultramarathon, buoyed by potential medical miracles and fraught with possible abuses.

As genomic data and its uses continue to balloon, it will be critical to curb potential abuse and ensure that the legacy of the HGP contributes to the betterment of all human lives, wrote Drs. Jennifer Rood and Aviv Regev at Genentech in a perspectives article for the issue.

Big data projects are a dime a dozen these days. A global effort to solve the brain? Yup. Scouring centenarians genes to find those that lead to longevity? Sure! Spitting in a tube to find out your ancestry and potential disease risksthe kits are on sale for the holidays! Genetically engineering anythingfrom yeast that brew insulin to an organism entirely new to Earthbeen there, done that!

These massive international collaborations and sci-fi stretch goals that we now take for granted owe their success to the HGP. Its had a profound effect on biomedical research, said Rood and Regev.

Flashback to the 1990s. Pulp Fiction played in theaters, Michael Jordan owned the NBA, and an international team decided to crack the base code of human life.

The study arose from years of frustration that genetic mapping tools needed better resolution. Scientists could roughly track down a gene related to certain types of genetic disorders, like Huntingtons disease, which is due to a single gene mutation. But it soon became clear that most of our toughest medical foes, such as cancer, often have multiple genetic hiccups. With the tools that were available at the time, solving these disorders was similar to debugging thousands of lines of code through a fogged-up lens.

Ultimately, the pioneers realized we needed an infinitely dense map of the genome to really begin decoding, said the authors. Meaning, we needed a whole picture of the human genome, at high resolution, and the tools to get it. Before the HGP, we were peeking at our genome through consumer binoculars. After it, we got the James Webb space telescope to look into our inner genetic universe.

The result was a human reference genome, a mold that nearly all biomedical studies map onto, from synthetic biology to chasing disease-causing mutants to the creation of CRISPR. Massive global consortiums, including the 1000 Genomes Project, the Cancer Genome Atlas, the BRAIN Initiative, and the Human Cell Atlas have all followed in HGPs steps. As a first big data approach to medicine, before the internet was ubiquitous, HGP laid out a new vision for collaborative science by openly sharing data from labs across the globesomething Covid-19 vaccines have benefited from.

Yet as with AOL, CDs, and Microsoft FrontPage, HGP may be a legacy product from a bygone era.

The first relatively finished reference genome was published in 2003. Yet two core questions at the heart of the HGP remain. One, what exactly should be considered a complete reference? Two, how can it be decoded to benefit humans?

Reference is an ambiguous idea in the age of increasingly cheaper genome sequencing. The original reference was what science considered an average human. It wasnt, but the reference genome did focus on mapping the most common variants in a gene. Yet its increasingly obvious that humans are wildly diverse in our genetic differences, which couldfor examplehave a say in our longevity.

Capturing the ever-growing genetic diversity of humans requires profiling a more diverse set of genomes, said the authors. Ultimately, although highly useful, a single reference genome is inherently biased. Your genealogy results from consumer kits, for example, could be on point or off base, depending on your race and the genetic background of their reference samples. For now, its mostly people with European ancestry.

The HGP and its legacy must serve humanity as a whole, not neglecting those who are currently underrepresented in biological research, the team said.

Then theres making sense of it. The HGP itself decoded the genome but didnt provide an understanding of itsuch as what genetic elements actually do, how they work together, and how they contribute to health and disease.

Were getting there, but slowly. Weve found genes that protect against Alzheimers, and genes that contribute to cancer and muscle disorders. Using a popular method called GWAS (genome-wide association study), scientists are increasingly capable of fishing out gene variantsoften hundreds at a timethat play a role in more complex disorders such as autism. But teasing out how bucketloads of genes affect any disease remains difficult. With the rise of machine learning and AI, however, the authors said, we have a powerful tool to begin unpacking its secrets to affect health.

Whats next? Thanks to ongoing massive whole genome sequencing projects, we could be shedding the veil of HGPs average human and entering a new era of multiple reference genomesor even personalized ones. With this would come massive concerns around privacy. The Golden State Killer case, though it had a happy ending in that it was ultimately solved, relied on a free and public genealogy database that people may not have knowingly agreed to partake in. Unexpected findings related to long-lost relatives, a high risk of serious diseases, or our own heritage, especially if shared with third parties, could damage relationships or even overthrow our sense of self.

From the idea of a reference genome to a smorgasbord of genetic tools, HGPs legacy is here to stay. As we move towards a more snowflake era of genomicsone that stresses individuality either for mixed-and-matched groups or individualsthe original goal remains the same.

The project left us with a major mission, still relevant even 20 years later, the authors said. We need to better understand how to wield our genetic blueprints, both common and rare, to promote human health and treat diseasefor all of humanity.

Image Credit: Thor DeichmannfromPixabay

Excerpt from:
Scientists Completed the First Human Genome 20 Years Ago. How Far Have We Come, and What's Next? - Singularity Hub

What we need tofightclimate change is woolly mammoths said no climate scientist, ever.

But thats not deterring a hotshot bioscience start-up from peddling its genetic tinkering as a way to reduce greenhouse gas emissions. On its slick website, newly-formed Colossal Laboratories prominently states that its top core goal is to decelerate melting of the arctic permafrost. Melting permafrost releases immense quantities of methane into the atmosphere, which contributes to global warming.

To achieve their stated goal, the founders plan to genetically engineer a hybrid of the Asian elephant and the extinct woolly mammoth, which lastlived about 4,000 years ago. If you dont immediately see how that relates to the climate crisis, hang on.

The pitch goes like this. First, the gene-splicing wizards will synthesize some carefully chosen woolly mammoth genes the animal'scomplete genetic sequence has been known since 2015 and implant them in an egg cell from an Asian elephant. Egg harvesting is hugely complex with elephants, and the Asian elephant is endangered. (Colossals fallback strategy is to make an embryo from stem cells.)

'What we need to fightclimate change is woolly mammoths' said no climate scientist, ever.

Next, theyll fertilize the egg and implant the modified embryo in an artificial womb. Actually, theres one step before that: inventing an artificial womb that can gestate a200-poundfetus for almost two years. Some preliminary experimental work with mice has been conducted, but that research utilized an embryo taken from a healthy mother mouse.

Once the baby mammoth-elephant emerges from the artificial womb, theyll need to raise it to maturity. That assumes that they figure out how to recreate the nurturing environment of an intensely social and highly intelligent species. And theyll need a lot of these babies to create a viable herd. Were finally getting to the climate part.

The next step is to relocate the herd to Siberia because thats where the permafrost is. According to Sergey Zimov, a Russian geophysicist who also does work in paleoecology, the introduction of the mammoth-elephants into the wet mossy tundra should induce the emergence of dry grasslands as they existed in the Late Pleistocene, roughly 10,00015,000 years ago.

This transformation of the arctic ecosystem, says Zimov, has multiple climate benefits. Grasslands will sequester more carbon in their root systems, and theyll reflect more sunlight, which reduces atmospheric heating.

And the big win is that when the mighty herds of mammoth-elephants trample insulating layers of snow, it will allow the frigid arctic air to chill the permafrost and thereby retain the ancient methane held within. Goal achieved.

Their disingenuous posturing debases the public discourse around climate change, which remains the planets most pressing issue.

But it doesnt pencil out. Suppose, optimistically, Colossal raises 100 healthy adult mammoth-elephants by 2040, and they double in population every 20 years. By 2200, they would have about 25,000 animals. Assuming you need a density of one beast per 10 square kilometers to have any ecological impact, those 25,000 would inhabit about one percent of Earths 22.8 million square kilometers of vulnerable permafrost.

So even if Colossal overcame the numerous formidable technological hurdles of creating hybrids of endangered elephants and an extinct relative, andthe company wasable to establish self-sustaining herds, and Zimovs fuzzy speculations about the effect of large herbivores on the tundra proved correct, the impact would be negligible even in 2200, a century after the climate crisis will likely be resolved, one way or the other.

The smart people at Colossal know this, so why are they selling us their bioscience venture as a climate change solution?

To answer that question, its helpful to look at the people involved. Lead scientist George Church of Harvard has been a disruptive rockstar in the genetics world for three decades. The business guy is whiz-kid serial entrepreneur Ben Lamm, who has already built a portfolio of successful high-tech start-ups.

And then there are the money guys.

Among the investors are the Winkelvoss twins, who made billions in Bitcoin after successfully suing Mark Zuckerberg for stealing the idea for Facebook. When asked how Colossal would make money, Cameron Winkelvoss suggested, there could be a lot of economic opportunity over time, which might include television or even parks for extinct animals, like"Jurassic Park.

The lead investor is billionaire movie producer Thomas Tull, founder of Legendary Entertainment, the company that co-produced the movie Jurassic World.

The prevalence of media executives and high-tech finance types in the Colossal boardroom makes you wonder if the companys ostensible environmental goals are secondary to a different agenda. There are zero climate scientists on their scientific advisory board. It seems likely that the true purpose of the ecosystems-cum-permafrost narrative is to leverage the virtuous cachet of fighting climate change and deflect ethical concerns around engineering transgenic species.

The financial backers will deem the company a success if it spins out some valuable genetic engineering tools or opens up new areas in the bioscience market, such as the artificial womb.

The woolly mammoth, the permafrost and the saving-the-planet facade are for creating headlines and media buzz, which wouldnt be so objectionable if climate change werent such a grave and urgent threat to the planets biosphere.

You can embrace the brilliant work Colossal is doing in genetics while rejecting the crass promotion of de-extinction as a meaningful climate measure. Their disingenuous posturing debases the public discourse around climate change, which remains the planets most pressing issue.

The crisis is escalating. Using climate advocacy as a phony marketing tool is a distraction we can ill afford.

Follow Cognoscenti on Facebook and Twitter.

Original post:
Dont Count On Woolly Mammoths To Save The Planet - WBUR

COVID appears to have been "tailor made for carnage" and may have escaped from the Wuhan lab after a scientist was bitten by an infected monkey, a bombshell new book has claimed.

Scientists have uncovered evidence that Covid was "exquisitely matched", "completely pre-adapted" and "supercharged" for humans when it first emerged in December 31.

3

It is suggested it had been meddled with and souped by in Frankenvirus experiments at the Wuhan lab at the eye of the storm over the origins of the pandemic.

And it is theorised this new virus - tampered with and ready to infect humans - may have leaked from the lab and gone on to kill 4.7million people worldwide.

Investigative journalist Sharri Markson's What really happened in Wuhan has uncovered a string of evidence pointing to the fact Covid could have been "genetically engineered" by the Wuhan Institute of Virology to make it more lethal.

For years, Markson said, Shi Zhengli - dubbed "batwoman" - has been manipulating viruses and inserting spike protein genes into coronaviruses to make them more infectious in humans.

The lab has a history of using techniques which can hide any traces of genetic engineering, and scientists have noted how Covid has highly unusual features - which point to a lab origin.

Markson said the answers to the origins of the pandemic lies in the unique genome of the virus.

Exclusive

"Its unique properties reveal so much about its likely origins as scientists, investigators and intelligence analysts seek to unravel its moment of inception," she said.

"This incredibly devastating virus is like no other, despite sharing properties with its SARS cousins. In character and behaviour it gives the impression it is purpose built to infect humans.

"It acts as if it's tailor made for human carnage, almost unstoppable in its capacity to ravage the human respiratory system.

"The millions dead all over the world attest to that."

It was completely pre-adapted to humans

And in one of the most sensational claims in the new book, former Donald Trump administration official David Asher revealed a whistleblower told him the virus may have escaped in an infected lab monkey biting a technician.

Asher was put in a touch with someone who claimed to have worked with Dr Shi Zhengli, China's so-called "Bat Woman".

The source told him "all hell had broken loose" at the lab with workers falling in around October 2019 - two months before China warned the world about Covid.

The scientist claimed the lab had been encouraged to do "hazardous" research by the Chinese military, which was later backed up by a second source.

And the lab worker claimed the outbreak had started from a monkey bite - with numerous labs in Wuhan known to have kept the animals.

However, Asher noted while he took the information seriously - he could not independently verify the claims and feared they could have been red herrings to throw the US of the scent in the hunt for the virus' origins.

3

Dr Steven Quay said the Wuhan lab has a history of making viruses "more virulent, more transmissible and more lethal"

He said Covid was "exquisitely matched" to humans, pointing to a possible lab origin.

"It was completely pre-adapted to humans," he told Markson. "This is the first virus from nature that has strong human-to-human transfer right from the beginning."

Dr Quay said the end result is always "supercharged" viruses.

And while examining the genome sequence of Covid, scientists found the genetic code for what is known as a "furin cleavage site".

Professor Richard Ebright said this is a "noteworthy" as it has never be seen before in coronaviruses, and it appears in the exact spot where scientists genetically tweak viruses to make them more infectious to humans.

In other words, a "furin cleavage site" boosts the ability of a virus to jump between species, and can also make it more transmissible within a species.

Nikolai Petrovsky, one of the scientists behind the development of the Covid vaccine, told Markson: "The issue is that the Covid-19 has a furin cleavage site whereas neither the bat virus that is its closest relative nor SARS have it.

"A question then is, where did Covid-19 get its furin cleavage site from?"

Petrovsky said the findings all point to a manmade virus - but the evidence was deemed "political dynamite" and scientific journals refused to the publish any papers on the clues.

"The virus spike protein looked like it couldn't have been better designed to fit the human," he said.

"The SARS-Cov-2 spike protein had uniquely evolved to bind and infect humans."

US physicist Richard Muller said the unique make-up of Covid is a "fingerprint of genetic manipulation".

"It's like finding a fingerprint at a crime scene," he said. "If you pick up a gun at a crime scene and find a fingerprint, this is not circumstantial evidence.

"This is the smoking gun.

"The furin cleavage site... the sequences that they splice in if you're really trying to attack humans, this is the fingerprint."

What Really Happened inWuhanby Sharri Markson is published by HarperCollins and out now, 20 (Hardback)

3

We pay for your stories!

Do you have a story for The Sun news desk?

See original here:
Covid was engineered by scientists for carnage and may have infected Patient Zero after MONKEY BITE, boo... - The US Sun

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, RevolutionaryPeople's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

Read more:
Guest editorial: Engineering the return of wooly mammoths? - Charleston Gazette-Mail

Investing in the stock market is more of an art than science. There is no single strategy that can guarantee success to investors. For instance, some investors prefer buying on dips, while some bet on the best-performing stocks. Both of these strategies are useful and may lead to returns as well, but it's important that investors need to be comfortable with the stock and the valuations. Thus, to help investors who are planning to invest in the best performing stocks, detailed below are the ten best performing stocks in September.

Q2 2021 hedge fund letters, conferences and more

We have used the past one month return data (from finviz.com) to rank the ten best performing stocks in September. For our list, we have only considered stocks with more than $10 billion in market cap. Following are the ten best performing stocks in September:

Founded in 1971, this company explores, develops and produces oil and natural gas properties. Devon Energy Corp (NYSE:DVN) develops and operates Barnett Shale, Heavy Oil, and more. The stock has returned more than 120% YTD and over 19% in the last three months. Devon Energy reported revenue of over $4.6 billion in 2020, down from over $6.3 billion in 2019. It is headquartered in Oklahoma City.

Founded in 1881, this company develops, produces and markets crude oil, natural gas liquids (NGLS), and natural gas in Canada. The stock has returned more than 65% YTD and over 1% in the last three months. Cenovus Energy Inc (NYSE:CVE) reported revenue of over $13.2 billion in 2020, down from over $20.1 billion in 2019. It is headquartered in Calgary, Canada.

Founded in 2008, it is a biotech company. Ginkgo Bioworks Holdings Inc (NASDAQ:SRNG) specializes in the use of genetic engineering to produce bacteria with industrial applications. Earlier this month, Soaring Eagle announced the transfer of listing to the NYSE in connection with its proposed business combination with Ginkgo. The stock has returned more than 22% in the last three months. Ginkgo Bioworks reported revenue of over $9.9 billion in 2020, down from over $17 billion in 2019. It is headquartered in Boston.

Story continues

Founded in 1985, this company explores, develops, produces and markets crude oil and natural gas. The stock has returned over 65% YTD, but is down more than 3% in the last three months. EOG Resources Inc (NYSE:EOG) reported revenue of over $9.9 billion in 2020, down from over $17 billion in 2019. It is headquartered in Houston.

Founded in 2007, it is an independent oil and natural gas company. Diamondback Energy Inc (NASDAQ:FANG) acquires, develops, explores and exploits unconventional, onshore oil and natural gas reserves. The stock has returned over 95% YTD, but is down more than 3% in the last three months. Diamondback Energy reported revenue of over $2.8 billion in 2020, down from over $3.9 billion in 2019. It is headquartered in Midland, Texas.

Founded in 1946, this firm makes and distributes nitrogen fertilizer. CF Industries Holdings, Inc. (NYSE:CF) owns and operates nitrogen plants, and serves agricultural and industrial customers. The stock has returned over 45% YTD and more than 7% in the last three months. CF Industries reported revenue of over $4.12 billion in 2020, down from over $4.59 billion in 2019. It is headquartered in Deerfield, Ill.

Founded in 2007, this company claims to be the pioneer in medical education. Lucid Group Inc (NASDAQ:LCID) works to enhance patients lives through healthcare communication. The stock has returned over 160% YTD, but is down more than 5% in the last three months. It is headquartered in London.

Founded in 2003, it is a biopharmaceutical company that discovers, develops and markets therapeutics to treat serious and rare diseases. The stock has returned over 35% YTD and more than 36% in the last three months. Acceleron Pharma Inc (NASDAQ:XLRN) reported revenue of over $92 million in 2020, an increase from over $73 million in 2019. It is headquartered in Cambridge, Mass.

Founded in 2008, this company develops a work management platform that allows teams to collaborate for routine tasks, as well as for specific projects. The stock has returned over 240% YTD and more than 60% in the last three months. Asana Inc (NYSE:ASAN) reported revenue of over $227 million in 2020, an increase from over $142 million in 2019. It is headquartered in San Francisco.

Founded in 2013, it is a cloud-based artificial intelligence lending platform. Upstart Holdings Inc (NASDAQ:UPST) primarily aggregates consumer demand for loans and then uses AI to connect them with its bank partners. The stock has returned over 600% YTD and more than 150% in the last three months. Upstart Holdings reported revenue of over $233 million in 2020, an increase from over $164 million in 2019. It is headquartered in San Mateo, Calif.

See the article here:
These Are The Ten Best Performing Stocks In September - Yahoo Finance

REHOVOT, Israel, Sept. 30, 2021 /PRNewswire/ -- CollPlantBiotechnologies (NASDAQ: CLGN),a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, has been invited to present at the Fall Harvest Best Ideas from the Buy-Side conference, which is being held virtually on October 5th 8th, 2021. Mr. Yehiel Tal, CollPlant's Chief Executive Officer, will present at the conference.

CollPlant is scheduled to present on October 5, 2021 at 8:30 AM-8:55 AM ET. Management will be available for one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2800/42994

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [emailprotected].

Investors can register here.

About the MicroCap Rodeo Summer Solstice Best Ideas ConferenceThe MicroCap Rodeo is back with its fourth "Best Ideas" conference. This conference is a virtual conference that brings you the top 35 best ideas from the buy side. Qualified institutional investors recommended each of the 35 companies represented as one of their best ideas. Those of you who attended the 2019 MicroCap Rodeo in Austin, Texas, know that we're focused on alpha.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its recombinant human collagen produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.

CollPlant recently entered a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.

For more information, visithttp://www.collplant.com.

Safe Harbor Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the impact of the COVID-19 pandemic; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact at CollPlant:Eran RotemDeputy CEO & Chief Financial OfficerTel: + 972-73-2325600/631Email:[emailprotected]

SOURCE CollPlant

Home

Continued here:
CollPlant to Present at Fall Harvest - Best Ideas from the Buy-Side on October 5, 2021 - PRNewswire

The resurrection of the wooly mammoth feels both dystopian and unattainable. But that is what our current science is, producing dystopian-like research to find what seems like unattainable findings. Its strange to think about. Which animal, who has been dead for thousands of years, gets the chance to come alive again-where do you draw the line? Is it unethical to release such a creature without knowing the implications it will have on our earth? While the resurrection will positively impact global warming, it will change the ecosystems and economics of the Siberian tundra forever. With all the unknowns, bringing back the wooly mammoth-or any extinct animal- is outside the ethics of scientific discovery.

Audrey, Glenbard West High School

Although I am full of excitement and hope to see the resurrected ancient species, I think genetic engineering is still a field that has not seen its full potential yet, and such innovative milestone will gather more attention and fund to more of these genetic projects. But when will we know how to stop is the issue. How will be able to say resurrecting a mammoth is right, while designing a baby to eliminate congenital disease is unethical. What is the rules we have for the field of DNA modification. Its best, I believe, to make proper rules even before this ancient beast is brought back to this world.

Noah, Japan

[W]e cant disregard the fact that this project, if it proves to be a success, would open up a gateway through our current bioethical barriers. Whats to stop someone from trying to replicate dead humans, when you could make the argument that it benefits us in some way? Animals go extinct for a reason, whether it be because they cant adapt, or because they are wiped out by some natural disaster, and bringing them back into an entirely different world is unpredictable, and not worth the risks that it poses; not when there are other, more plausible solutions to the problem.

Anna, Glenbard West High School

Scientists are only predicting and not analyzing what Wooly Mammoths could do for the environment. Because of how speculative it is, its potential dangers are almost innumerable. Take the Burmese Python as an example for invasive species. It was accidentally released into Florida and ran uncontrollably rampant all over the Everglades region, now threatening many of the local species. It is still a pressing issue today, showing how even with our technology, controlling disasters like these is near impossible.

Gilbert, Kempner High School

Although there might be some short term benefit to nature, the true result is very unpredictable and wont really go the way that the researchers expect it to go. In an ecosystem, each organism has its own niche or role, and is related to another organism in the food cycle, which is basically how the whole ecosystem regulates and maintains its structure. Any disruption to this food cycle, will just end up causing long term issues to the ecosystem, as it alter the lives of all the other organisms in a fashion that we cannot predict, as they will be exposed to this completely new creature.

Loken, Farmington High School

In a sentence: Not Yet. Keeping personal beliefs on the morality and ethics of such efforts aside, let us consider the practical consequences of this issue. Potentially reintroducing a long-extinct species into our world current ecosystem would undoubtably impact all living organisms on earth in a manner we cannot predict. On one hand, it could be argued that the purpose of science is to continually expand our understanding of the world and what possible in it. Overall, giving back life to species is not a decision that can be taken back, Unless we have a solid reasoning for why genetically resurrecting species would be in our best interests, it would be better to wait. Jurassic Park said it best, Just because we can, doesnt mean we should.

Ananya, Farmington High School

No, we should not bring animals back from extinction. We should be more focused on saving the ones about to go extinct rather than the ones that already are. Most animals went extinct because of climate change. Thanks to humans not working to correct the problem with climate change but making it worse, we are slowly killing everything and everyone. Those animals that have gone extinct have served their time and purpose on earth. Therefore, we should spend our time and resources focusing on those that are about to go extinct. We are about to lose Lemurs, polar bears, gorillas, etcetera. Humans should be figuring out a way to save their habitats, preserve their food sources, and do whatever else it takes to keep these animals, along with others from, becoming extinct.

Tevana, Cary, NC

Excerpt from:
What Students Are Saying About Teaching Race in Schools, Reviving Extinct Animals and Live Sports - The New York Times

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the Companys induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021.

The oral presentation will highlight preclinical data for FT536, the Companys off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate that uniquely targets the 3 domain of the MHC class I related proteins A (MICA) and B (MICB). In a recent publication in Cancer Immunology Research (DOI: 10.1158/2326-6066.CIR-19-0483), Kai W. Wucherpfennig, M.D., Ph.D., Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and co-leader of the Cancer Immunology Program at Dana-Farber / Harvard Cancer Center, demonstrated that cancers with loss of MHC Class I expression can be effectively targeted with MICA/B 3 domain-specific antibodies to restore NK cell-mediated immunity against solid tumors. The FT536 program is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics. The Company expects to submit an Investigational New Drug (IND) application for FT536 in the fourth quarter of 2021 for the treatment of advanced solid tumors, including in combination with monoclonal antibody therapy.

Poster presentations at SITC will include preclinical data on new functional elements that the Company is evaluating for incorporation into its iPSC-derived cell product candidates for solid tumors. These synthetic features include engineered chemokine receptors, which the Company has demonstrated can enhance the trafficking and homing of iPSC-derived CAR T cells to tumors, and synthetic TGF re-direct receptors, which the Company has shown can exploit immuno-suppressive cytokines found in the tumor microenvironment to potentiate iPSC-derived CAR T cells and improve anti-tumor activity.

Oral Presentation

Poster Presentation

About MICA and MICB ProteinsThe major histocompatibility complex (MHC) class I related proteins A (MICA) and B (MICB) are induced by cellular stress, damage or transformation, and the expression of MICA and MICB proteins has been reported for many tumor types. Cytotoxic lymphocytes, such as NK cells and CD8+ T cells, can detect and bind the membrane-distal 1 and 2 domains of MICA/B, activating a potent cytotoxic response. However, cancer cells frequently evade immune cell recognition by proteolytic shedding of the 1 and 2 domains of MICA/B. The clinical importance of proteolytic shedding is reflected in the association of high serum concentrations of shed MICA/B with disease progression in many solid tumors. Several recent publications have shown that therapeutic antibodies targeting the membrane-proximal 3 domain strongly inhibited MICA/B shedding, resulting in a substantial increase in the cell surface density of MICA/B and restoration of NK cell-mediated tumor immunity (DOI:10.1126/science.aao0505). Therapeutic approaches aimed at targeting the 3 domain of MICA/B therefore represent a potentially promising novel strategy to overcome this prominent evasion mechanism as a means of restoring anti-tumor immunity.

About Fate Therapeutics iPSC Product PlatformThe Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Companys clinical studies and preclinical research and development programs, its ongoing and planned clinical studies, and the safety and therapeutic potential of the Companys product candidates. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Companys product candidates may not demonstrate the requisite safety or efficacy to achieve regulatory approval or to warrant further development, the risk that results observed in prior studies of the Companys product candidates, including preclinical studies and clinical trials of any of its product candidates, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Companys product candidates or in the initiation of, or enrollment of patients in, any clinical studies, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, the amount and type of data to be generated, or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Companys ongoing and planned clinical trials, difficulties in manufacturing or supplying the Companys product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com

More here:
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting - StreetInsider.com